MiMedx Q2 net sales $64M (-35% YoY); to acquire Sanara MedTech for ~$350M

MIMEDX GROUP, INC.

Net sales $64M vs $99M YoY; net loss $15M vs net income $10M YoY.
Surgical product sales +15% YoY; Wound sales -61% YoY due to Medicare changes.
Acquiring Sanara MedTech (SMTI) for $35/share ($33 cash + 0.4735 MDXG shares); ~$350M enterprise value.
Consideration represents 46% premium to Sanara's 30-day VWAP; expected close by year-end.
Financing via cash on hand and $300M term loan from Hayfin; FY2026 net sales guidance reiterated at $260-290M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.